The Section for Analysis and Research

The Section for Analysis and Research at The Registry Department covers two important purposes for The Norwegian Cancer Registry; information and research.
Last updated: 10/12/2021

The Section for Analysis and Research produces statistics for national clinical registries at the Cancer Registry and follows up with more advanced analyses where necessary. The national clinical registries aim to strengthen the quality of the health care provided to cancer patients. Data from the registries can also help to detect unwanted differences in cancer care.

Together with the Data Flow section, this section also produces statistics for The Norwegian Cancer Registry's annual report Cancer in Norway.

The group has a research focus on cancer burden and clinical cancer epidemiology, and more recently on patient reported health and quality of life. Cancer patients are invited to answer questionnaires about self-perceived health and quality of life, with the aim to improve cancer care and knowledge about life after cancer.

Key research areas

• Social inequalities and unwanted differences in cancer and treatment
Cancer patient pathways in Norway
• Immigrants and cancer
• Development of cancer epidemiology methods, in particular survival            methods                                                                                                • Patient-reported outcome measures

Participation in international research projects on incidence and survival

We participate in several international collaborations which compare cancer incidence, mortality, prevalence and survival after cancer.

Cancer incidence, treatment and outcomes in Europe:

EUROCARE - Survival og cancer patients in Europe

European Registration of Cancer Care

International Cancer Benchmarking Partnership (ICBP)

Cancer Survival Group

Cancer incidence, treatment and results in the Nordic countries:

Improved survival for cancer patients in a large Nordic comparison 

Selected publications from the research group

Publications 2021

Langseth ØOMyklebust TÅJohannesen TBHjertner ØWaage A (2021)
Patterns of previous and secondary malignancies in patients with multiple myeloma
Eur J Haematol (in press)
DOI 10.1111/ejh.13581PubMed 33455012

Andersson TMMyklebust TÅRutherford MJMøller BSoerjomataram IArnold MBray FParkin DMSasieni PBucher ODe PEngholm GGavin ALittle APorter GRamanakumar AVSaint-Jacques NWalsh PMWoods RRLambert PC (2021)
The impact of excluding or including Death Certificate Initiated (DCI) cases on estimated cancer survival: A simulation study
Cancer Epidemiol71 (Pt A)101881 (in press)
DOI 10.1016/j.canep.2020.101881PubMed 33440295

Almås BHalvorsen OJJohannesen TBBeisland C (2021)
Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study
World J Urol
DOI 10.1007/s00345-020-03576-3PubMed 33420812

Publications 2020

Larsen IKMyklebust TÅBabigumira RVinberg EMøller BUrsin G (2020)
Education, income and risk of cancer: results from a Norwegian registry-based study
Acta Oncol59 (11)1300-1307
DOI 10.1080/0284186X.2020.1817548PubMed 32924698

Reigstad MMStoreng RFuru KBakken IJEngeland ALarsen IK (2020)
Validation of Assisted Reproductive Technology in the Medical Birth Registry of Norway Versus the Norwegian Prescription Database
Epidemiology31 (5)681-686
DOI 10.1097/EDE.0000000000001228PubMed 32639249

Thøgersen H, Møller BÅsli LMBhargava SKvåle RFjellbirkeland LRobsahm TEAaserud SBabigumira RLarsen IK (2020)
Waiting times and treatment following cancer diagnosis: comparison between immigrants and the Norwegian host population
Acta Oncol59 (4)376-383
DOI 10.1080/0284186X.2019.1711167PubMed 31920119

Kvåle RBønaa KHForster RGravningen KJúlíusson PBMyklebust TÅ (2020)
Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection?
Tidsskr Nor Laegeforen140 (2)
DOI 10.4045/tidsskr.20.0956PubMed 33528146

Hellesnes RMyklebust TÅBremnes RMKarlsdottir ÁKvammen ØNegaard HFSTandstad TWilsgaard TFosså SDHaugnes HS (2020)
Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study
J Clin Oncol39 (4)308-318
DOI 10.1200/JCO.20.02713PubMed 33356420

Vatne Monsen KFosså SDDahl AAMyklebust TÅSmeland SStensvold A (2020)
Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life
Scand J Urol55 (1)9-16
DOI 10.1080/21681805.2020.1854343PubMed 33349097

Andersson TMRutherford MJMyklebust TÅMøller BSoerjomataram IArnold MBray FParkin DMSasieni PBucher ODe PEngholm GGavin ALittle APorter GRamanakumar AVSaint-Jacques NWalsh PMWoods RRLambert PC (2020)
Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study
Br J Cancer
DOI 10.1038/s41416-020-01196-7PubMed 33293692

Brancher SStøer NCWeiderpass EDamhuis RAMJohannesen TBBotteri EStrand TE (2020)
Metformin use and lung cancer survival: a population-based study in Norway
Br J Cancer
DOI 10.1038/s41416-020-01186-9PubMed 33262518

Ursin GGrimsrud TKGulbrandsen JJakobsen EJohannesen TBLarønningen SRobsahm TESeglem AHMøller BLarsen IK (2020)
Kreft i Norge
Tidsskr Nor Laegeforen140 (17)
DOI 10.4045/tidsskr.20.0853PubMed 33231394

Gullestad HPHaugen GFosså SD (2020)
Late arm and shoulder problems after axillary therapeutic lymph node dissection in patients with melanoma
J Plast Surg Hand Surg
DOI 10.1080/2000656X.2020.1842746PubMed 33176535

Bjerring AWFosså SDHaugnes HSNome RStokke TMHaugaa KHKiserud CEEdvardsen TSarvari SI (2020)
The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up
Eur Heart J Cardiovasc Imaging (in press)
DOI 10.1093/ehjci/jeaa289PubMed 33152065

Dahl AAFosså SDBrennhovd BAxcrona K (2020)
The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism
Int Urol Nephrol
DOI 10.1007/s11255-020-02688-4PubMed 33118115

Fosså SDAas KMüller CJerm MBTandstad TLilleby WKvåle RGulbrandsen JHaug EMyklebust TA (2020)
Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival
Radiother Oncol15533-41 (in press)
DOI 10.1016/j.radonc.2020.10.022PubMed 33096165

Lundberg FEAndersson TMLambe MEngholm GMørch LSJohannesen TBVirtanen APettersson DÓlafsdóttir EJBirgisson HJohansson ALVLambert PC (2020)
Trends in cancer survival in the Nordic countries 1990-2016: the NORDCAN survival studies
Acta Oncol59 (11)1266-1274
DOI 10.1080/0284186X.2020.1822544PubMed 33073632

Lambert PCAndersson TMRutherford MJMyklebust TÅMøller B (2020)
Reference-adjusted and standardized all-cause and crude probabilities as an alternative to net survival in population-based cancer studies
Int J Epidemiol49 (5)1614-1623
DOI 10.1093/ije/dyaa112PubMed 32829393

Hjerkind KVLarsen IKAaserud SMøller B, Ursin G (2020)
Cancer incidence in non-immigrants and immigrants in Norway
Acta Oncol59 (11)1275-1283
DOI 10.1080/0284186X.2020.1817549PubMed 32930622

Blindheim AFosså SBabigumira RMyklebust TÅHaug EArum CJAndreassen BK (2020)
T1 bladder cancer in Norway: treatment and survival
Scand J Urol54 (5)370-375
DOI 10.1080/21681805.2020.1803401PubMed 32783590

Aas KDorothea Fosså SÅge Myklebust TMøller BKvåle RVlatkovic LBerge V (2020)
Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study
Cancer Med9 (18)6646-6657
DOI 10.1002/cam4.3297PubMed 32750229

Stewart RFosså SDHotopf MMykletun A (2020)
Extent of disease at first cancer presentation and previous anxiety and depressive symptoms: the HUNT study
Br J Psychiatry217 (2)427-433
DOI 10.1192/bjp.2019.211PubMed 31587671

Fosså SDDahl AAMyklebust TÅKiserud CENome RKlepp OHBrydøy MHaugnes HS (2020)
Risk of positive selection bias in longitudinal surveys among cancer survivors: Lessons learnt from the national Norwegian Testicular Cancer Survivor Study
Cancer Epidemiol67101744
DOI 10.1016/j.canep.2020.101744PubMed 32652337

Myklebust TÅAndersson TBardot AVernon SGavin AFitzpatrick DJerm MBRutherford MParkin DMSasieni PArnold MSoerjomataram IBray FLambert PCMøller B (2020)
Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study
Cancer Epidemiol67101759
DOI 10.1016/j.canep.2020.101759PubMed 32544801

Trewin CBJohansson ALVHjerkind KVStrand BHKiserud CEUrsin G (2020)
Stage-specific survival has improved for young breast cancer patients since 2000: but not equally
Breast Cancer Res Treat182 (2)477-489
DOI 10.1007/s10549-020-05698-zPubMed 32495000

Nilssen YBrustugun OTEriksen MTHaug ESNaume BMøller B (2020)
Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
BMC Cancer20 (1)488
DOI 10.1186/s12885-020-06979-yPubMed 32473650

Groen JVDouwes TAvan Eycken Evan der Geest LGMJohannesen TBBesselink MGKoerkamp BGWilmink JWBonsing BAPortielje JEAvan de Velde CJHBastiaannet EMieog JSDDutch Pancreatic Cancer Group (2020)
Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
Ann Surg Oncol27 (13)5337-5346
DOI 10.1245/s10434-020-08539-xPubMed 32388741

Langseth ØOMyklebust TÅJohannesen TBHjertner ØWaage A (2020)
Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017
Br J Haematol191 (3)418-425
DOI 10.1111/bjh.16674PubMed 32367512

Trewin CBHjerkind KVJohansson ALVStrand BHKiserud CEUrsin G (2020)
Socioeconomic inequalities in stage-specific breast cancer incidence: a nationwide registry study of 1.1 million young women in Norway, 2000-2015
Acta Oncol59 (11)1284-1290
DOI 10.1080/0284186X.2020.1753888PubMed 32319848

Lenartova AJohannesen TBTjønnfjord GE (2020)
Chronic lymphocytic leukemia and secondary hematological malignancies: A nation-wide cancer registry study
Eur J Haematol104 (6)546-553
DOI 10.1111/ejh.13396PubMed 32058605

Nome RVCvancarova Småstuen MBjøro TKiserud CEFosså SD (2020)
Longitudinal kidney function outcome in aging testicular cancer survivors
Acta Oncol59 (4)467-474
DOI 10.1080/0284186X.2020.1724328PubMed 32043400

Dahl AABrennhovd BFosså SDAxcrona K (2020)
A cross-sectional study of current work ability after radical prostatectomy
BMC Urol20 (1)9
DOI 10.1186/s12894-020-0579-9PubMed 32005115